~~<i id='73256EDADC'><strike id='73256EDADC'><tt id='73256EDADC'><pre id='73256EDADC'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：hotspot 2025-09-06 06:00:49 Page View：32

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hospitals warn Medicare's drug payment fix is ‘unlawful’
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Readout Newsletter: XBI biotech index, Akero Therapeutics

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Medicare proceeds with plan to claw back hospital funds

AdobeWASHINGTON— Medicareofficialsaremovingforwardwithaplantoclawbackmoneyfromcertainhospitalstotryt